安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMGN 安进

交易中 05-05 15:32:29 EDT

326.95

+3.10

+0.96%

最高327.48	最低320.53	成交量211.84万
今开322.25	昨收323.85	日振幅2.15%
总市值1,761亿	流通市值1,756亿	总股本5.38亿
成交额6.87亿	换手率0.39%	流通股本5.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"安进","latestPrice":326.954,"timestamp":1778009548106,"preClose":323.85,"halted":0,"volume":2118445,"delay":0,"changeRate":0.009584684267407703,"floatShares":536994627,"shares":538480671,"eps":14.368346,"marketStatus":"交易中","change":3.104,"latestTime":"05-05 15:32:29 EDT","open":322.25,"high":327.48,"low":320.53,"amount":687041583.5745,"amplitude":0.021461,"askPrice":327.08,"askSize":42,"bidPrice":326.94,"bidSize":88,"shortable":3,"etf":0,"ttmEps":14.368346,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1778011200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":323.85,"dividendRate":0.029517,"preHourTrading":{"tag":"盘前","latestPrice":321.81,"preClose":323.85,"latestTime":"09:29 EDT","volume":3689,"amount":1188976.79992,"timestamp":1777987799999,"change":-2.04,"changeRate":-0.006299,"amplitude":0.011443},"postHourTrading":{"tag":"盘后","latestPrice":321.9,"preClose":323.85,"latestTime":"19:58 EDT","volume":179410,"amount":58102200.5891,"timestamp":1777939085895,"change":-1.95,"changeRate":-0.006021,"amplitude":0.006021},"volumeRatio":0.720812,"impliedVol":0.2615,"impliedVolPercentile":0.2948},"requestUrl":"/m/hq/s/AMGN","defaultTab":"news","newsList":[{"id":"1146480534","title":"安进追加3亿美元美国制造投资，过去一年总投资额逼近20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146480534","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146480534?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:01","pubTimestamp":1777899680,"startTime":"0","endTime":"0","summary":"生物技术巨头安进公司宣布将向其美国制造业务追加3亿美元投资，这一举措使其在过去12个月内对美国本土生产设施的总投入达到近20亿美元。\n此次最新投资延续了安进强化国内供应链的战略布局，彰显了公司对提升生物制药产能的长期承诺。近20亿美元的资本注入将用于现代化生产设备升级和新技术平台部署，以支持创新疗法的规模化生产。\n作为全球生物制药领域的领导者，安进持续加大在美国的制造投入，这不仅有助于保障关键药品的稳定供应，也将为当地创造更多高技能就业岗位。公司表示，这项投资将进一步提升其应对未来医疗需求的能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU1983299246.USD","LU0122379950.USD","AMGN","IE00B4R5TH58.HKD","LU2242652126.USD","LU0058720904.USD","IE0002141913.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","BK4585","LU1023059063.AUD","BK4534","LU2112291526.USD","BK4139","IE00B2B36J28.USD","LU2242646821.SGD","BK4599","LU1571399168.USD","LU1061106388.HKD","SG9999001440.SGD","BK4581","IE0009355771.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","LU0868494617.USD","LU1057294990.SGD","LU2468319806.SGD","BK4533","LU2089984988.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","BK4566","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107055076","title":"安进提交Cbe-30文件修订肝毒性警示语 为Tavneos相关血管炎病例提供更详细信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1107055076","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107055076?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:03","pubTimestamp":1777579396,"startTime":"0","endTime":"0","summary":"生物制药巨头安进公司近日向监管机构提交了Cbe-30类别文件，对其产品标签中的肝毒性警告内容进行了重要修订。此次更新特别针对与Tavneos相关的血管炎病例信息披露进行了强化，在原有警示基础上补充了更具临床参考价值的病例数据。这一调整体现了安进对药物安全监测的持续重视，旨在帮助医生更准确地评估用药风险收益比。公司表示将继续密切监测Tavneos在真实世界应用中的安全性表现，确保患者用药安全。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU0320765992.SGD","BK4581","IE00B4R5TH58.HKD","LU0122379950.USD","BK4534","LU0109394709.USD","LU1057294990.SGD","LU1571399168.USD","IE0009355771.USD","LU0289739699.SGD","BK4585","LU2089984988.USD","SG9999001440.SGD","BK4588","BK4139","IE0002141913.USD","LU2242652126.USD","LU0058720904.USD","LU0868494617.USD","IE00BFTCPJ56.SGD","LU1983299246.USD","BK4566","BK4533","AMGN","IE00B2B36J28.USD","LU2112291526.USD","LU0889565916.HKD","IE00BJT1NW94.SGD","BK4599","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112223752","title":"安进计划与FDA展开沟通 坚信Tavneos展现疗效及良好获益-风险特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1112223752","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112223752?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:02","pubTimestamp":1777579369,"startTime":"0","endTime":"0","summary":"生物技术巨头安进公司表示，计划与美国食品药品监督管理局（FDA）进行积极沟通。该公司持续坚信，其药物Tavneos在临床应用中展现出显著疗效，并具备良好的获益-风险特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU2112291526.USD","LU0868494617.USD","BK4599","LU0122379950.USD","LU0889565916.HKD","LU1061106388.HKD","LU0320765992.SGD","LU0109394709.USD","BK4566","BK4588","LU2089984988.USD","BK4534","LU1571399168.USD","IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU1057294990.SGD","IE00B4R5TH58.HKD","LU2468319806.SGD","LU1983299246.USD","BK4585","AMGN","LU0058720904.USD","LU2242652126.USD","BK4581","SG9999001440.SGD","LU1023059063.AUD","LU0289739699.SGD","IE0002141913.USD","BK4533","IE00BJJMRZ35.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193530232","title":"FDA明确：Tavneos将继续在市场销售，直至申请人主动撤市或局长强制要求","url":"https://stock-news.laohu8.com/highlight/detail?id=1193530232","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193530232?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:44","pubTimestamp":1777337053,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）近日发布声明，针对药物Tavneos的市场地位作出明确表态。该药物将继续在市场上合法销售，其去留将取决于两种情形：一是由申请方（即制药公司）自行决定将其撤市；二是由FDA局长行使职权，强制要求其退出市场。此举为Tavneos的未来提供了明确的监管框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B2B36J28.USD","BK4581","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU0889565916.HKD","LU0868494617.USD","LU2089984988.USD","LU2242652126.USD","IE0009355771.USD","LU0320765992.SGD","LU1057294990.SGD","LU0058720904.USD","LU1983299246.USD","AMGN","IE0002141913.USD","LU2468319806.SGD","SG9999001440.SGD","IE00BJT1NW94.SGD","LU2112291526.USD","LU1023059063.AUD","LU0109394709.USD","BK4599","BK4533","LU0289739699.SGD","BK4588","LU2242646821.SGD","BK4585","IE00BJJMRZ35.SGD","LU1571399168.USD","LU0122379950.USD","BK4566","BK4534","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182507856","title":"财报前瞻｜安进本季度营收预计增6.60%，机构观点看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1182507856","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182507856?lang=zh_cn&edition=full","pubTime":"2026-04-23 08:14","pubTimestamp":1776903287,"startTime":"0","endTime":"0","summary":"安进将于2026年04月30日发布最新季度财报，市场普遍预期营收与盈利延续温和增长，关注管线催化对收入结构与利润率的影响。依据当前一致预期，本季度安进营收预计为85.89亿美元，同比增长6.60%；调整后每股收益预计为4.76美元，同比增长10.79%；息税前利润预计为36.30亿美元，同比增长9.07%；市场未提供本季度毛利率与净利率或净利润的预测数据，相关指标暂不展示。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜安进本季度营收预计增6.60%，机构观点看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627415479","title":"百济神州年营收382亿：净利14.6亿 安进与Baker是核心股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2627415479","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627415479?lang=zh_cn&edition=full","pubTime":"2026-04-15 09:52","pubTimestamp":1776217938,"startTime":"0","endTime":"0","summary":"百济神州有限公司（公司代码：688235 公司简称：百济神州）日前发布截至2025年12月31日的财报。财报显示，百济神州2025年营收为382.25亿，较上年同期的272亿增长40.46%；","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260415/6391184353468399959612189.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260415/6391184353468399959612189.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33283/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["688235","ONC","06160","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627498112","title":"港股异动 | 再鼎医药(09688)涨超3% 近日与安进达成全球临床合作 Zoci正处于全球注册性临床III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2627498112","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627498112?lang=zh_cn&edition=full","pubTime":"2026-04-14 09:46","pubTimestamp":1776131184,"startTime":"0","endTime":"0","summary":"消息面上，近日，再鼎医药官微宣布，公司与安进公司达成一项全球临床研究合作，旨在评估再鼎医药处于临床阶段的靶向delta样配体3的抗体药物偶联物zocilurtatug pelitecan联合安进IMDELLTRA，一款靶向DLL3的双特异性T细胞衔接器疗法，用于治疗广泛期小细胞肺癌患者。作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09688","ZLAB","BK4585","BK4566","IE00BJT1NW94.SGD","IE0009355771.USD","LU2112291526.USD","VXUS","IE00B2B36J28.USD","LU1983299246.USD","BK4588","LU0320765992.SGD","BK4531","LU0109394709.USD","BK4548","BK4599","LU0122379950.USD","LU0289739699.SGD","BK1588","LU0889565916.HKD","BK1161","BK4533","LU1571399168.USD","BK4134","LU0058720904.USD","IE00B4R5TH58.HKD","IE0002141913.USD","SG9999001440.SGD","LU2488822045.USD","BK4534","IE00BFTCPJ56.SGD","BK4526","BK4139","LU1061106388.HKD","IE00BJJMRZ35.SGD","III","LU2089984988.USD","LU2242646821.SGD","LU1057294990.SGD","LU2468319806.SGD","AMGN","LU2242652126.USD","LU0868494617.USD","BK4581","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626198497","title":"安进肺癌药物他拉妥单抗获中国批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626198497","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626198497?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:40","pubTimestamp":1775810400,"startTime":"0","endTime":"0","summary":"安进研发合作伙伴及商业化合作方贝达药业周五在微信平台宣布，安进的肺癌药物他拉妥单抗已获中国国家药品监督管理局批准。该药属于安进管线中的双特异性抗体药物，其作用机制是同时结合癌细胞与免疫细胞，使人体免疫系统能够杀伤癌细胞。　　安进与在港上市的贝达药业均未就该药物在中国市场的上市时间及定价回应置评请求。　　部分华尔街分析师表示，他拉妥单抗有望为安进带来每年超 20 亿美元的销售收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-10/doc-inhtzamv8056323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0058720904.USD","IE00B2B36J28.USD","BK4534","LU2242652126.USD","LU2089984988.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","IE0009355771.USD","LU0320765992.SGD","SG9999001440.SGD","LU1983299246.USD","BK4585","BK4533","BK4566","LU0868494617.USD","IE00B4R5TH58.HKD","BK4588","AMGN","LU1571399168.USD","LU1061106388.HKD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU1057294990.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD","LU2242646821.SGD","BK4581","BK4139","LU2468319806.SGD","LU0289739699.SGD","BK4599","LU2112291526.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148371895","title":"安进公布Tepezza皮下注射剂治疗中重度活动性甲状腺眼病成人患者的积极三期顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1148371895","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148371895?lang=zh_cn&edition=full","pubTime":"2026-04-06 21:00","pubTimestamp":1775480413,"startTime":"0","endTime":"0","summary":"安进公司宣布，其Tepezza皮下注射剂针对中重度活动性甲状腺眼病成人患者的三期临床试验取得积极顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU0109394709.USD","LU0889565916.HKD","LU1983299246.USD","LU0868494617.USD","LU2089984988.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4139","LU2242646821.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4534","LU1061106388.HKD","LU0289739699.SGD","LU1571399168.USD","LU2242652126.USD","BK4566","LU0122379950.USD","BK4581","LU0320765992.SGD","BK4588","LU1023059063.AUD","BK4585","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","AMGN","BK4533","IE0009355771.USD","LU1057294990.SGD","LU2112291526.USD","SG9999001440.SGD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151218584","title":"安进：Tepezza三期试验总体安全性结果与静脉注射Tepezza已知安全性特征基本一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1151218584","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151218584?lang=zh_cn&edition=full","pubTime":"2026-04-06 21:00","pubTimestamp":1775480413,"startTime":"0","endTime":"0","summary":"安进公司公布的最新数据显示，其Tepezza药物在三期临床试验中的总体安全性结果，与静脉注射Tepezza已知的安全性特征大体相符。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU0289739699.SGD","LU2112291526.USD","BK4534","IE00BJT1NW94.SGD","LU0122379950.USD","LU0868494617.USD","LU1023059063.AUD","BK4139","BK4566","IE0002141913.USD","BK4599","LU2242646821.SGD","IE00BFTCPJ56.SGD","SG9999001440.SGD","BK4533","LU2089984988.USD","LU0109394709.USD","LU0320765992.SGD","IE0009355771.USD","LU1571399168.USD","BK4585","LU1057294990.SGD","BK4581","LU1061106388.HKD","IE00B4R5TH58.HKD","BK4588","IE00B2B36J28.USD","LU2242652126.USD","LU1983299246.USD","LU0058720904.USD","AMGN","LU0889565916.HKD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624524927","title":"再鼎医药午前涨近5% 与安进公司达成一项全球临床研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624524927","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624524927?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:37","pubTimestamp":1775101020,"startTime":"0","endTime":"0","summary":"　　再鼎医药午前涨超4%，截至发稿，股价上涨4.82%，现报15.88港元，成交额2.88亿港元。　　作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-02/doc-inhtaraa1102717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AMGN","LU0109394709.USD","LU1057294990.SGD","BK4139","BK4548","BK4534","LU0122379950.USD","LU2242652126.USD","BK4566","SG9999001440.SGD","LU0289739699.SGD","BK4533","LU0058720904.USD","BK4581","LU2242646821.SGD","IE0009355771.USD","LU0868494617.USD","BK4588","BK1574","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4599","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK1588","LU2488822045.USD","BK4526","BK1161","IE00BJT1NW94.SGD","09688","LU1983299246.USD","ZLAB","BK4585","LU2112291526.USD","LU1061106388.HKD","LU2468319806.SGD","LU0889565916.HKD","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4531","LU1023059063.AUD","IE0002141913.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624556767","title":"美国FDA就与安进罕见病药物有关的肝损伤病例发出警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2624556767","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624556767?lang=zh_cn&edition=full","pubTime":"2026-04-01 14:48","pubTimestamp":1775026119,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1983299246.USD","LU2242652126.USD","BK4581","BK4566","BK4588","IE00BJT1NW94.SGD","LU0289739699.SGD","IE0009355771.USD","LU2242646821.SGD","LU2468319806.SGD","LABU","LU0320765992.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD","BK4533","LU2112291526.USD","LU0058720904.USD","LU1571399168.USD","IE0002141913.USD","BK4139","LU1057294990.SGD","LU0889565916.HKD","AMGN","IE00B4R5TH58.HKD","LU0122379950.USD","SG9999001440.SGD","BK4585","LU0868494617.USD","IE00BJJMRZ35.SGD","BK4599","BK4534","LU1061106388.HKD","IE00B2B36J28.USD","LU2089984988.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179256799","title":"FDA警示：Tavneos出现胆管消失综合征及致死性药物性肝损伤病例 构成新安全隐患","url":"https://stock-news.laohu8.com/highlight/detail?id=1179256799","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179256799?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:10","pubTimestamp":1774962657,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）近期发布安全警示，抗炎药物Tavneos（avacopan）在临床使用中出现了胆管消失综合征及致死性药物性肝损伤的病例报告，这些严重不良反应构成了该药物新的安全性隐忧。\n胆管消失综合征是一种罕见的严重肝损伤，其特征为肝内胆管进行性破坏消失。而此次报告的药物性肝损伤病例已出现致命后果。监管机构指出，医疗专业人员需对接受Tavneos治疗的患者保持高度警惕，密切监测其肝功能指标。\n此次安全信号的浮现，为Tavneos的风险效益评估增添了新的考量维度。临床医生在处方时应充分权衡其治疗潜力与潜在的严重肝毒性风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","BK4588","BK4139","IE0002141913.USD","LU1023059063.AUD","LU0868494617.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU0889565916.HKD","IE0009355771.USD","LU0289739699.SGD","BK4599","LU0320765992.SGD","BK4585","BK4533","LU1061106388.HKD","IE00B2B36J28.USD","LU0109394709.USD","LU1571399168.USD","LU1983299246.USD","BK4534","IE00B4R5TH58.HKD","SG9999001440.SGD","BK4566","AMGN","IE00BJJMRZ35.SGD","LU2468319806.SGD","BK4581","LU0122379950.USD","LU2242646821.SGD","LU2242652126.USD","IE00BJT1NW94.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192752433","title":"安进公布Vesalius-Cv三期临床试验结果：Repatha显著降低心肌梗死、冠心病死亡及缺血性卒中风险","url":"https://stock-news.laohu8.com/highlight/detail?id=1192752433","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192752433?lang=zh_cn&edition=full","pubTime":"2026-03-29 04:46","pubTimestamp":1774730776,"startTime":"0","endTime":"0","summary":"安进公司宣布，其开展的Vesalius-Cv三期临床试验取得积极成果。数据显示，使用Repatha（瑞百安）可显著降低患者发生心肌梗死、冠心病相关死亡以及缺血性卒中的综合风险。\n该临床试验结果进一步证实了Repatha在心血管疾病二级预防中的治疗价值，为存在心血管事件高风险的患者提供了重要的临床证据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999001440.SGD","LU0889565916.HKD","BK4581","LU2242646821.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","AMGN","LU1057294990.SGD","LU1983299246.USD","IE0009355771.USD","BK4534","BK4533","LU2468319806.SGD","LU0289739699.SGD","IE00B4R5TH58.HKD","LU1571399168.USD","LU0058720904.USD","IE00B2B36J28.USD","LU1023059063.AUD","LU0320765992.SGD","BK4585","BK4566","IE00BJT1NW94.SGD","LU0109394709.USD","LU2112291526.USD","LU2242652126.USD","LU2089984988.USD","LU1061106388.HKD","LU0868494617.USD","BK4599","LU0122379950.USD","BK4588","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146126461","title":"EMA人用药品委员会：Joenja（Leniolisib）获特殊情况下上市许可积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1146126461","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146126461?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:45","pubTimestamp":1774611913,"startTime":"0","endTime":"0","summary":"欧洲药品管理局（EMA）人用药品委员会（CHMP）已对Joenja（Leniolisib）发出积极意见，建议其在特殊情况下授予上市许可。这一关键进展为特定患者群体的治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0109394709.USD","LU2089984988.USD","LU2242646821.SGD","IE00B2B36J28.USD","IE0009355771.USD","BK4585","BK4599","LU0122379950.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU0320765992.SGD","BK4581","BK4566","IE00BFTCPJ56.SGD","LU0289739699.SGD","BK4588","LU1061106388.HKD","LU2242652126.USD","LU2112291526.USD","IE00BJT1NW94.SGD","BK4533","IE0002141913.USD","BK4139","BK4534","LU1057294990.SGD","LU0868494617.USD","SG9999001440.SGD","LU1571399168.USD","AMGN","LU2468319806.SGD","LU0058720904.USD","LU0889565916.HKD","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109151850","title":"欧洲药品管理局人用医药产品委员会建议批准Imdylltra（Tarlatamab）用于复发广泛期小细胞肺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1109151850","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109151850?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:43","pubTimestamp":1774611797,"startTime":"0","endTime":"0","summary":"欧洲药品管理局人用医药产品委员会（CHMP）近日发布积极意见，建议授予安进公司开发的靶向疗法Imdylltra（Tarlatamab）上市许可。该药物拟用于治疗既往接受过系统性治疗的复发广泛期小细胞肺癌患者。\n此次推荐基于关键临床研究数据，显示Tarlatamab作为双特异性T细胞衔接抗体，能显著激活患者自身免疫系统攻击肿瘤细胞。若最终获欧盟委员会批准，这将成为首款针对该适应症的靶向免疫疗法，为预后极差的晚期肺癌群体提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU2089984988.USD","BK4599","BK4581","IE0002141913.USD","LU0109394709.USD","LU2242646821.SGD","LU2112291526.USD","BK4585","BK4533","IE0009355771.USD","BK4139","LU0122379950.USD","LU0868494617.USD","LU2468319806.SGD","BK4566","LU0058720904.USD","LU1057294990.SGD","LU1023059063.AUD","LU1571399168.USD","SG9999001440.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BJT1NW94.SGD","BK4588","LU1983299246.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4534","LU0289739699.SGD","LU2242652126.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149822474","title":"协和麒麟：数周内安全审查揭示恶性肿瘤新风险，或与病毒及免疫因素相关","url":"https://stock-news.laohu8.com/highlight/detail?id=1149822474","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149822474?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:05","pubTimestamp":1772543110,"startTime":"0","endTime":"0","summary":"协和麒麟公司近期完成的安全评估显示，在过去数周的分析中发现新型恶性肿瘤风险信号，这些潜在病例可能与病毒感染或免疫系统异常存在关联。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","IE00B4R5TH58.HKD","BK4139","BK4588","LU2112291526.USD","LU1061106388.HKD","IE0002141913.USD","LU0122379950.USD","BK4581","BK4534","LU1571399168.USD","LU0109394709.USD","LU0058720904.USD","LU0289739699.SGD","LU0868494617.USD","IE00BJT1NW94.SGD","IE0009355771.USD","AMGN","LU0889565916.HKD","LU2242646821.SGD","LU2089984988.USD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU2242652126.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4533","LU1023059063.AUD","LU2468319806.SGD","LU0320765992.SGD","BK4585","BK4566","LU1983299246.USD","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610684644","title":"Argus上调安进目标价至400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610684644","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610684644?lang=zh_cn&edition=full","pubTime":"2026-02-09 15:22","pubTimestamp":1770621743,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BFTCPJ56.SGD","BK4534","LU0320765992.SGD","LU1023059063.AUD","LU2468319806.SGD","LU0122379950.USD","LU1983299246.USD","LU1571399168.USD","LU0109394709.USD","LU0289739699.SGD","IE0009355771.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2242652126.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","BK4585","LU2089984988.USD","BK4581","LU0058720904.USD","LU2112291526.USD","AMGN","IE00BJT1NW94.SGD","LU1061106388.HKD","BK4599","LU0889565916.HKD","LU2242646821.SGD","IE0002141913.USD","BK4566","LU1057294990.SGD","BK4533","BK4139","BK4588","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609324007","title":"花旗上调安进目标价至345美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609324007","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609324007?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:27","pubTimestamp":1770280021,"startTime":"0","endTime":"0","summary":"花旗将安进的目标价从315美元上调至345美元，维持“中性”评级。(格隆汇)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260205/32000802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129271059","title":"安进核心业务强劲增长，抵消减肥药上市延迟影响——市场快评","url":"https://stock-news.laohu8.com/highlight/detail?id=1129271059","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129271059?lang=zh_cn&edition=full","pubTime":"2026-02-05 03:58","pubTimestamp":1770235106,"startTime":"0","endTime":"0","summary":"尽管安进公司的新型减肥药物尚需进一步测试，但其核心产品正持续推动业绩增长。威廉·布莱尔分析师指出，虽然投资者目光聚焦于减肥疗法MariTide，但该药关键的第三阶段试验结果预计要到2027年才能揭晓。在此期间，降胆固醇药物瑞百安与哮喘治疗药Tezspire等核心产品正为短期增长提供动力。\n值得注意的是，安进发布的2026年初步营收指引超出市场预期，彰显出现有产品组合的强劲实力。尽管肥胖治疗领域竞争激烈，威廉·布莱尔仍维持\"跑赢大盘\"评级，认为该股未来仍存重要临床催化剂。当前安进股价涨幅达8.5%。\n（本文根据市场公开信息整理，不构成投资建议）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","IE00B2B36J28.USD","BK4533","BK4588","BK4581","IE0002141913.USD","LU1571399168.USD","IE0009355771.USD","LU0889565916.HKD","LU0058720904.USD","LU2112291526.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","AMGN","IE00B4R5TH58.HKD","LU2242646821.SGD","LU0122379950.USD","LU2468319806.SGD","BK4585","BK4139","LU1983299246.USD","LU2089984988.USD","BK4534","LU1061106388.HKD","LU0320765992.SGD","BK4599","LU1057294990.SGD","SG9999001440.SGD","LU0109394709.USD","BK4566","LU2242652126.USD","LU0289739699.SGD","IE00BJJMRZ35.SGD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":-0.048},{"period":"1month","weight":-0.0692},{"period":"3month","weight":-0.0435},{"period":"6month","weight":0.0125},{"period":"1year","weight":0.1516},{"period":"ytd","weight":-0.0106}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0948},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0597},{"period":"1year","weight":0.2669},{"period":"ytd","weight":0.0529}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Amgen Inc是一家生物技术公司。该公司从事发现、开发、生产和提供治疗最棘手疾病的药物。该公司专注于医疗需求尚未得到满足的领域，并利用专业知识努力寻求改善人们生活的解决方案。该公司在人类治疗领域开展业务。该公司的营销产品组合包括EPOGEN（阿法依泊汀）、Aranesp（阿法达贝泊汀）、Parsabiv（etelcalcetide）、Neulasta（培非格司亭）；KANJINTI（曲妥珠单抗）、Otezla、BLINCYTO（blinatumomab）、ACTIMMUNE（干扰素γ-1b）、Neulasta（培非格司亭）、Sensipar/Mimpara（西那卡塞）、Prolia（地舒单抗）、ENBREL、QUINSAIR（左氧氟沙星）、Repatha（依洛尤单抗）等。该公司在美国和加拿大销售肿瘤坏死因子阻断剂ENBREL。该公司在全球许多国家销售抑制磷酸二酯酶4的小分子药物Otezla。该公司在全球许多国家销售前蛋白转化酶枯草溶菌素/kexin 9型 (PCSK9) 抑制剂Repatha。","yearOnYearQuotes":[{"month":1,"riseRate":0.651163,"avgChangeRate":0.034336},{"month":2,"riseRate":0.488372,"avgChangeRate":0.00202},{"month":3,"riseRate":0.511628,"avgChangeRate":0.016602},{"month":4,"riseRate":0.44186,"avgChangeRate":-0.003156},{"month":5,"riseRate":0.511628,"avgChangeRate":0.022112},{"month":6,"riseRate":0.5,"avgChangeRate":0.003875},{"month":7,"riseRate":0.767442,"avgChangeRate":0.052562},{"month":8,"riseRate":0.604651,"avgChangeRate":0.004451},{"month":9,"riseRate":0.511628,"avgChangeRate":0.002296},{"month":10,"riseRate":0.534884,"avgChangeRate":0.021538},{"month":11,"riseRate":0.627907,"avgChangeRate":0.022348},{"month":12,"riseRate":0.627907,"avgChangeRate":0.045446}],"exchange":"NASDAQ","name":"安进","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安进,AMGN,安进股票,安进股票老虎,安进股票老虎国际,安进行情,安进股票行情,安进股价,安进股市,安进股票价格,安进股票交易,安进股票购买,安进股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}